The End­points News poll: Should the FDA pan­el back an ap­proval for ad­u­canum­ab, or should they send Bio­gen pack­ing?

There’s been a con­sid­er­able amount of back-and-forth over the rel­a­tive mer­its, or lack there­of, in Bio­gen’s ap­pli­ca­tion to mar­ket the Alzheimer’s drug ad­u­canum­ab.

Bio­gen ex­ecs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER